img

Global and United States Orally Administered Vaccine Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Orally Administered Vaccine Market Report & Forecast 2024-2034

Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. 
Market Analysis and InsightsGlobal and United States Orally Administered Vaccine Market
This report focuses on global and United States Orally Administered Vaccine market, also covers the segmentation data of other regions in regional level and county level.
The global Orally Administered Vaccine revenue was US$ 2540 million in 2024 and is forecast to a readjusted size of US$ 3746.5 million by 2034 with a CAGR of 5.7% during the forecast period (2024-2034).
In United States the Orally Administered Vaccine revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Orally Administered Vaccine include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. The global five biggest players hold a share of % in 2024.
Global Orally Administered Vaccine Scope and Market Size
Orally Administered Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Orally Administered Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Orally Administered Vaccine market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other

Segment by Application


Public
Private
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Orally Administered Vaccine definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Orally Administered Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Orally Administered Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orally Administered Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Orally Administered Vaccine Product Introduction
1.2 Global Orally Administered Vaccine Outlook 2018 VS 2024 VS 2034
1.2.1 Global Orally Administered Vaccine Sales in US$ Million for the Year 2018-2034
1.2.2 Global Orally Administered Vaccine Sales in Volume for the Year 2018-2034
1.3 United States Orally Administered Vaccine Outlook 2018 VS 2024 VS 2034
1.3.1 United States Orally Administered Vaccine Sales in US$ Million for the Year 2018-2034
1.3.2 United States Orally Administered Vaccine Sales in Volume for the Year 2018-2034
1.4 Orally Administered Vaccine Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of United States Orally Administered Vaccine in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Orally Administered Vaccine Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.5 Orally Administered Vaccine Market Dynamics
1.5.1 Orally Administered Vaccine Industry Trends
1.5.2 Orally Administered Vaccine Market Drivers
1.5.3 Orally Administered Vaccine Market Challenges
1.5.4 Orally Administered Vaccine Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Orally Administered Vaccine by Type
2.1 Orally Administered Vaccine Market Segment by Type
2.1.1 Rotavirus Vaccine
2.1.2 Cholera Vaccine
2.1.3 Oral Polio Vaccine
2.1.4 Other
2.2 Global Orally Administered Vaccine Market Size by Type
2.2.1 Global Orally Administered Vaccine Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Orally Administered Vaccine Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 United States Orally Administered Vaccine Market Size by Type
2.3.1 United States Orally Administered Vaccine Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 United States Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 United States Orally Administered Vaccine Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Orally Administered Vaccine by Application
3.1 Orally Administered Vaccine Market Segment by Application
3.1.1 Public
3.1.2 Private
3.2 Global Orally Administered Vaccine Market Size by Application
3.2.1 Global Orally Administered Vaccine Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Orally Administered Vaccine Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 United States Orally Administered Vaccine Market Size by Application
3.3.1 United States Orally Administered Vaccine Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 United States Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 United States Orally Administered Vaccine Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Orally Administered Vaccine Competitor Landscape by Company
4.1 Global Orally Administered Vaccine Market Size by Company
4.1.1 Global Key Manufacturers of Orally Administered Vaccine, Ranked by Revenue (2024)
4.1.2 Global Orally Administered Vaccine Revenue by Manufacturer (2018-2023)
4.1.3 Global Orally Administered Vaccine Sales by Manufacturer (2018-2023)
4.1.4 Global Orally Administered Vaccine Price by Manufacturer (2018-2023)
4.2 Global Orally Administered Vaccine Concentration Ratio (CR)
4.2.1 Orally Administered Vaccine Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Orally Administered Vaccine in 2024
4.2.3 Global Orally Administered Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Orally Administered Vaccine, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Orally Administered Vaccine, Product Offered and Application
4.5 Global Key Manufacturers of Orally Administered Vaccine, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Orally Administered Vaccine Market Size by Company
4.7.1 Key Players of Orally Administered Vaccine in United States, Ranked by Revenue (2024)
4.7.2 United States Orally Administered Vaccine Revenue by Players (2018-2023)
4.7.3 United States Orally Administered Vaccine Sales by Players (2018-2023)
5 Global Orally Administered Vaccine Market Size by Region
5.1 Global Orally Administered Vaccine Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Orally Administered Vaccine Market Size in Volume by Region (2018-2034)
5.2.1 Global Orally Administered Vaccine Sales in Volume by Region: 2018-2023
5.2.2 Global Orally Administered Vaccine Sales in Volume Forecast by Region (2024-2034)
5.3 Global Orally Administered Vaccine Market Size in Value by Region (2018-2034)
5.3.1 Global Orally Administered Vaccine Sales in Value by Region: 2018-2023
5.3.2 Global Orally Administered Vaccine Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Orally Administered Vaccine Market Size YoY Growth 2018-2034
6.2 Americas Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Orally Administered Vaccine Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Orally Administered Vaccine Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Orally Administered Vaccine Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Orally Administered Vaccine Market Size YoY Growth 2018-2034
7.2 EMEA Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Orally Administered Vaccine Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Orally Administered Vaccine Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Orally Administered Vaccine Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Orally Administered Vaccine Market Size YoY Growth 2018-2034
8.2 China Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Orally Administered Vaccine Market Size YoY Growth 2018-2034
9.2 APAC Orally Administered Vaccine Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Orally Administered Vaccine Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Orally Administered Vaccine Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Orally Administered Vaccine Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Orally Administered Vaccine Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Description and Business Overview
10.1.3 Merck Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Orally Administered Vaccine Products Offered
10.1.5 Merck Recent Development
10.2 GSK
10.2.1 GSK Company Information
10.2.2 GSK Description and Business Overview
10.2.3 GSK Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GSK Orally Administered Vaccine Products Offered
10.2.5 GSK Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Description and Business Overview
10.3.3 Sanofi Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sanofi Orally Administered Vaccine Products Offered
10.3.5 Sanofi Recent Development
10.4 Lanzhou Institute
10.4.1 Lanzhou Institute Company Information
10.4.2 Lanzhou Institute Description and Business Overview
10.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Lanzhou Institute Orally Administered Vaccine Products Offered
10.4.5 Lanzhou Institute Recent Development
10.5 Serum Institute
10.5.1 Serum Institute Company Information
10.5.2 Serum Institute Description and Business Overview
10.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Serum Institute Orally Administered Vaccine Products Offered
10.5.5 Serum Institute Recent Development
10.6 Valneva
10.6.1 Valneva Company Information
10.6.2 Valneva Description and Business Overview
10.6.3 Valneva Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Valneva Orally Administered Vaccine Products Offered
10.6.5 Valneva Recent Development
10.7 Shanghai United Cell
10.7.1 Shanghai United Cell Company Information
10.7.2 Shanghai United Cell Description and Business Overview
10.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Shanghai United Cell Orally Administered Vaccine Products Offered
10.7.5 Shanghai United Cell Recent Development
10.8 Bibcol
10.8.1 Bibcol Company Information
10.8.2 Bibcol Description and Business Overview
10.8.3 Bibcol Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bibcol Orally Administered Vaccine Products Offered
10.8.5 Bibcol Recent Development
10.9 PaxVax
10.9.1 PaxVax Company Information
10.9.2 PaxVax Description and Business Overview
10.9.3 PaxVax Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 PaxVax Orally Administered Vaccine Products Offered
10.9.5 PaxVax Recent Development
10.10 Vabiotech
10.10.1 Vabiotech Company Information
10.10.2 Vabiotech Description and Business Overview
10.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Vabiotech Orally Administered Vaccine Products Offered
10.10.5 Vabiotech Recent Development
10.11 Tiantan Biological
10.11.1 Tiantan Biological Company Information
10.11.2 Tiantan Biological Description and Business Overview
10.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Tiantan Biological Orally Administered Vaccine Products Offered
10.11.5 Tiantan Biological Recent Development
10.12 EuBiologics
10.12.1 EuBiologics Company Information
10.12.2 EuBiologics Description and Business Overview
10.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 EuBiologics Orally Administered Vaccine Products Offered
10.12.5 EuBiologics Recent Development
10.13 Panacea Biotec Ltd
10.13.1 Panacea Biotec Ltd Company Information
10.13.2 Panacea Biotec Ltd Description and Business Overview
10.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Panacea Biotec Ltd Orally Administered Vaccine Products Offered
10.13.5 Panacea Biotec Ltd Recent Development
10.14 Bio-Med
10.14.1 Bio-Med Company Information
10.14.2 Bio-Med Description and Business Overview
10.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Bio-Med Orally Administered Vaccine Products Offered
10.14.5 Bio-Med Recent Development
10.15 Halfkin Bio-Pharmaceuticals
10.15.1 Halfkin Bio-Pharmaceuticals Company Information
10.15.2 Halfkin Bio-Pharmaceuticals Description and Business Overview
10.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Products Offered
10.15.5 Halfkin Bio-Pharmaceuticals Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Orally Administered Vaccine Industry Chain Analysis
11.2 Orally Administered Vaccine Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Orally Administered Vaccine Production Mode & Process
11.4 Orally Administered Vaccine Sales and Marketing
11.4.1 Orally Administered Vaccine Sales Channels
11.4.2 Orally Administered Vaccine Distributors
11.5 Orally Administered Vaccine Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Orally Administered Vaccine CAGR in Value, United States VS Global, 2018 VS 2024 VS 2034
Table 2. Orally Administered Vaccine Market Trends
Table 3. Orally Administered Vaccine Market Drivers
Table 4. Orally Administered Vaccine Market Challenges
Table 5. Orally Administered Vaccine Market Restraints
Table 6. Global Orally Administered Vaccine Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Orally Administered Vaccine Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Orally Administered Vaccine Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Orally Administered Vaccine Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Orally Administered Vaccine, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Orally Administered Vaccine Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Orally Administered Vaccine Revenue Share by Manufacturer, 2018-2023
Table 13. Global Orally Administered Vaccine Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Orally Administered Vaccine Sales Share by Manufacturer, 2018-2023
Table 15. Global Orally Administered Vaccine Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Orally Administered Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Orally Administered Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orally Administered Vaccine as of 2024)
Table 18. Global Key Manufacturers of Orally Administered Vaccine, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Orally Administered Vaccine, Product Offered and Application
Table 20. Global Key Manufacturers of Orally Administered Vaccine, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Orally Administered Vaccine in United States, Ranked by Revenue (2024) & (US$ million)
Table 23. United States Orally Administered Vaccine Revenue by Players, (US$ Million), (2018-2023)
Table 24. United States Orally Administered Vaccine Revenue Share by Players, (2018-2023)
Table 25. United States Orally Administered Vaccine Sales by Players, (K Units), (2018-2023)
Table 26. United States Orally Administered Vaccine Sales Share by Players, (2018-2023)
Table 27. Global Orally Administered Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Orally Administered Vaccine Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Orally Administered Vaccine Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Orally Administered Vaccine Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Orally Administered Vaccine Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Orally Administered Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Orally Administered Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Orally Administered Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Orally Administered Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Orally Administered Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Orally Administered Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Orally Administered Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Orally Administered Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Orally Administered Vaccine Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Orally Administered Vaccine Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Orally Administered Vaccine Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Orally Administered Vaccine Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Merck Company Information
Table 48. Merck Description and Business Overview
Table 49. Merck Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Merck Orally Administered Vaccine Product
Table 51. Merck Recent Development
Table 52. GSK Company Information
Table 53. GSK Description and Business Overview
Table 54. GSK Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. GSK Orally Administered Vaccine Product
Table 56. GSK Recent Development
Table 57. Sanofi Company Information
Table 58. Sanofi Description and Business Overview
Table 59. Sanofi Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Sanofi Orally Administered Vaccine Product
Table 61. Sanofi Recent Development
Table 62. Lanzhou Institute Company Information
Table 63. Lanzhou Institute Description and Business Overview
Table 64. Lanzhou Institute Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Lanzhou Institute Orally Administered Vaccine Product
Table 66. Lanzhou Institute Recent Development
Table 67. Serum Institute Company Information
Table 68. Serum Institute Description and Business Overview
Table 69. Serum Institute Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Serum Institute Orally Administered Vaccine Product
Table 71. Serum Institute Recent Development
Table 72. Valneva Company Information
Table 73. Valneva Description and Business Overview
Table 74. Valneva Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Valneva Orally Administered Vaccine Product
Table 76. Valneva Recent Development
Table 77. Shanghai United Cell Company Information
Table 78. Shanghai United Cell Description and Business Overview
Table 79. Shanghai United Cell Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Shanghai United Cell Orally Administered Vaccine Product
Table 81. Shanghai United Cell Recent Development
Table 82. Bibcol Company Information
Table 83. Bibcol Description and Business Overview
Table 84. Bibcol Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Bibcol Orally Administered Vaccine Product
Table 86. Bibcol Recent Development
Table 87. PaxVax Company Information
Table 88. PaxVax Description and Business Overview
Table 89. PaxVax Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. PaxVax Orally Administered Vaccine Product
Table 91. PaxVax Recent Development
Table 92. Vabiotech Company Information
Table 93. Vabiotech Description and Business Overview
Table 94. Vabiotech Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Vabiotech Orally Administered Vaccine Product
Table 96. Vabiotech Recent Development
Table 97. Tiantan Biological Company Information
Table 98. Tiantan Biological Description and Business Overview
Table 99. Tiantan Biological Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Tiantan Biological Orally Administered Vaccine Product
Table 101. Tiantan Biological Recent Development
Table 102. EuBiologics Company Information
Table 103. EuBiologics Description and Business Overview
Table 104. EuBiologics Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. EuBiologics Orally Administered Vaccine Product
Table 106. EuBiologics Recent Development
Table 107. Panacea Biotec Ltd Company Information
Table 108. Panacea Biotec Ltd Description and Business Overview
Table 109. Panacea Biotec Ltd Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Panacea Biotec Ltd Orally Administered Vaccine Product
Table 111. Panacea Biotec Ltd Recent Development
Table 112. Bio-Med Company Information
Table 113. Bio-Med Description and Business Overview
Table 114. Bio-Med Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Bio-Med Orally Administered Vaccine Product
Table 116. Bio-Med Recent Development
Table 117. Halfkin Bio-Pharmaceuticals Company Information
Table 118. Halfkin Bio-Pharmaceuticals Description and Business Overview
Table 119. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product
Table 121. Halfkin Bio-Pharmaceuticals Recent Development
Table 122. Key Raw Materials Lists
Table 123. Raw Materials Key Suppliers Lists
Table 124. Orally Administered Vaccine Customers List
Table 125. Orally Administered Vaccine Distributors List
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Orally Administered Vaccine Product Picture
Figure 2. Global Orally Administered Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Orally Administered Vaccine Market Size 2018-2034 (US$ Million)
Figure 4. Global Orally Administered Vaccine Sales 2018-2034 (K Units)
Figure 5. United States Orally Administered Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. United States Orally Administered Vaccine Market Size 2018-2034 (US$ Million)
Figure 7. United States Orally Administered Vaccine Sales 2018-2034 (K Units)
Figure 8. United States Orally Administered Vaccine Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. United States Orally Administered Vaccine Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Orally Administered Vaccine Report Years Considered
Figure 11. Product Picture of Rotavirus Vaccine
Figure 12. Product Picture of Cholera Vaccine
Figure 13. Product Picture of Oral Polio Vaccine
Figure 14. Product Picture of Other
Figure 15. Global Orally Administered Vaccine Market Share by Type in 2024 & 2034
Figure 16. Global Orally Administered Vaccine Sales in Value by Type (2018-2034) & (US$ Million)
Figure 17. Global Orally Administered Vaccine Sales Market Share in Value by Type (2018-2034)
Figure 18. Global Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 19. Global Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 20. Global Orally Administered Vaccine Price by Type (2018-2034) & (US$/Unit)
Figure 21. United States Orally Administered Vaccine Market Share by Type in 2024 & 2034
Figure 22. United States Orally Administered Vaccine Sales in Value by Type (2018-2034) & (US$ Million)
Figure 23. United States Orally Administered Vaccine Sales Market Share in Value by Type (2018-2034)
Figure 24. United States Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 25. United States Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 26. United States Orally Administered Vaccine Price by Type (2018-2034) & (US$/Unit)
Figure 27. Product Picture of Public
Figure 28. Product Picture of Private
Figure 29. Global Orally Administered Vaccine Market Share by Application in 2024 & 2034
Figure 30. Global Orally Administered Vaccine Sales in Value by Application (2018-2034) & (US$ Million)
Figure 31. Global Orally Administered Vaccine Sales Market Share in Value by Application (2018-2034)
Figure 32. Global Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 33. Global Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 34. Global Orally Administered Vaccine Price by Application (2018-2034) & (US$/Unit)
Figure 35. United States Orally Administered Vaccine Market Share by Application in 2024 & 2034
Figure 36. United States Orally Administered Vaccine Sales in Value by Application (2018-2034) & (US$ Million)
Figure 37. United States Orally Administered Vaccine Sales Market Share in Value by Application (2018-2034)
Figure 38. United States Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 39. United States Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 40. United States Orally Administered Vaccine Price by Application (2018-2034) & (US$/Unit)
Figure 41. Americas Orally Administered Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 42. Americas Orally Administered Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 43. Americas Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 44. Americas Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 45. Americas Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 46. Americas Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 47. United States Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 48. Canada Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Mexico Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. EMEA Orally Administered Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 52. EMEA Orally Administered Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 53. EMEA Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 54. EMEA Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 55. EMEA Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 56. EMEA Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 57. Europe Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 58. Middle East Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Africa Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. China Orally Administered Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 61. China Orally Administered Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 62. China Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 63. China Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 64. China Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 65. China Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 66. APAC Orally Administered Vaccine Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 67. APAC Orally Administered Vaccine Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 68. APAC Orally Administered Vaccine Sales by Type (2018-2034) & (K Units)
Figure 69. APAC Orally Administered Vaccine Sales Market Share in Volume by Type (2018-2034)
Figure 70. APAC Orally Administered Vaccine Sales by Application (2018-2034) & (K Units)
Figure 71. APAC Orally Administered Vaccine Sales Market Share in Volume by Application (2018-2034)
Figure 72. Japan Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 73. South Korea Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. China Taiwan Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. India Orally Administered Vaccine Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. Orally Administered Vaccine Value Chain
Figure 78. Orally Administered Vaccine Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed